Literature DB >> 14742136

Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9.

S L Boye1, O Kerdpin, D J Elliot, J O Miners, L Kelly, R A McKinnon, C R Bhasker, K Yoovathaworn, D J Birkett.   

Abstract

1. Methods for the co-expression in Escherichia coli of human cytochrome P450 (CYP) 2C8 and CYP2C9 with NADPH-cytochrome P450 reductase (OxR) to produce a catalytically active system were compared. 2. Approaches assessed were expression of a CYP:OxR fusion construct, bicistronic plasmids, simultaneous transformation with CYP and OxR plasmids, and separate expression of CYP and OxR with reconstitution of activity by mixing the bacterial membranes. Two N-terminal modifications (Delta3-20 and 17alpha-leader) of the individual P450s were additionally investigated. 3. Each approach gave efficient expression of CYP2C8 and CYP2C9, but the bicistronic constructs under the expression conditions used gave low OxR expression and low catalytic activity. CYP expression was higher with the Delta3-20 construct for CYP2C9 and with the 17alpha-presequence construct for CYP2C8. 4. Using torsemide as substrate, all methods gave catalytically active systems with K(m) values similar to human liver microsomes. Mixing bacterial membranes containing separately expressed CYP and OxR reconstituted a catalytically active system with the Delta3-20 construct for CYP2C9 but not for CYP2C8, and with neither of the 17alpha- presequence constructs. OxR co-expressed with CYP in the same membrane interacted with CYP to reconstitute activity more effectively than addition of exogenous OxR membranes. 5. Expression construct and OxR co-expression strategy should be individualized for CYP isoforms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742136     DOI: 10.1080/00498250310001636868

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  3 in total

1.  An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

Authors:  Thomas M Polasek; David J Elliot; Andrew A Somogyi; Elizabeth M J Gillam; Benjamin C Lewis; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

2.  In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.

Authors:  Nitsupa Wattanachai; Thomas M Polasek; Tahlia M Heath; Verawan Uchaipichat; Wongwiwat Tassaneeyakul; Wichittra Tassaneeyakul; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2011-02-09       Impact factor: 2.953

3.  Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Authors:  David J Elliot; Benjamin C Lewis; Elizabeth M J Gillam; Donald J Birkett; Annette S Gross; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.